JULIA MELVIN: Open Payments
NPI 1104087881 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,371 in 76 payments from 11 companies in 2025. Trend: 2023 $873 · 2024 $1,161 · 2025 $2,371
Food & beverage: $2,371
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 24 | $1,007 |
| Gilead Sciences, Inc. | 25 | $579 |
| Ipsen Biopharmaceuticals, Inc | 10 | $319 |
| Intercept Pharmaceuticals, Inc. | 4 | $183 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 2 | $69 |
| ABBVIE INC. | 3 | $55 |
| Novo Nordisk Inc | 1 | $20 |
| Eton Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific Corporation | 1 | $19 |
Products named: REZDIFFRA, IQIRVO, OCALIVA, Vemlidy, XIFAXAN, MAVYRET, BEVESPI AEROSPHERE, Wegovy.
Industry payments across AZ — which companies pay providers there.
